Commentary 10.1172/JCI128481
1Case Cardiovascular Research Institute and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
2Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Mukesh K. Jain, Iris & Bert L. Wolstein Research Building, 2103 Cornell Road, Cleveland, Ohio 44106, USA. Phone: 216.368.3391; Email: mxj84@case.edu.
Find articles by Sweet, D. in: JCI | PubMed | Google Scholar
1Case Cardiovascular Research Institute and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
2Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Mukesh K. Jain, Iris & Bert L. Wolstein Research Building, 2103 Cornell Road, Cleveland, Ohio 44106, USA. Phone: 216.368.3391; Email: mxj84@case.edu.
Find articles by Fan, L. in: JCI | PubMed | Google Scholar
1Case Cardiovascular Research Institute and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
2Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Mukesh K. Jain, Iris & Bert L. Wolstein Research Building, 2103 Cornell Road, Cleveland, Ohio 44106, USA. Phone: 216.368.3391; Email: mxj84@case.edu.
Find articles by Jain, M. in: JCI | PubMed | Google Scholar
First published April 29, 2019 - More info
Glucocorticoids (GCs) are essential for proper glycemic control, but in excess, can lead to hyperglycemia and diabetes. In this issue of the JCI, Cui et al. elucidate a mechanism by which GCs regulate gluconeogenesis utilizing the transcription factor Krüppel-like factor 9 (KLF9) in physiology and disease settings. They report that KLF9 is a GC-inducible factor that ultimately increases the transcription of proliferator-activated receptor γ coactivator 1 α (PGC1α), resulting in gluconeogenesis. Given the high incidence of GC-induced diabetes, identification of this signaling axis provides, not only critical scientific insight, but also a foundation for preventative therapies for patients receiving chronic GC treatment.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.